|drug4083||zinc acetate Wiki||0.58|
|drug3724||chlorine dioxide Wiki||0.58|
|drug3993||revised HOME-CoV score Wiki||0.58|
|D003141||Communicable Diseases NIH||0.12|
|D014777||Virus Diseases NIH||0.06|
There are 3 clinical trials
A retrospective case series of patients who self-medicated with Famotidine during coronavirus disease 2019 (COVID-19). The study will collect de-identified patient reported outcome measures of patients with confirmed COVID-19 who self-medicated with Famotidine at any dose during the period of illness. Data will be collected by questionnaire and telephone interview. Inclusion criteria: Age>18; Ability to give written informed consent for study participation; Confirmed diagnosis of COVID-19; Use of Famotidine at any dose during period of COVID-19 illness
Description: Symptoms assessed by severity scores on an ordinal scale; 1=not affected to 4= severely affectedMeasure: Symptomatic improvement Time: 2 weeks
Description: Oxygen saturation determined by pulse oximetryMeasure: Peripheral blood oxygen saturation Time: 2 weeks
The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.
Description: Data will be collected and entered into Case Report Form in local REDCap sever to include MedDRA Code, Grade and all other data required by NIH per Memorandum, "Guidance for Collection of Adverse Events Related to COVID-19 Infection" dated on 25 March 2020. All data will be reported per this memorandum and in accordance with all applicable Institutional Review Board and FDA requirements.Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: 0 to 3 months
This is a platform study to investigate the effectiveness of a variety of non-prescription approaches for the treatment of non-hospitalized adults recently tested positive for COVID-19.
Description: Symptoms of COVID-19 will be evaluated daily using a visual analogue scaleMeasure: Reduction in Participant Symptoms of COVID-19 Time: 3 days
Description: Participants will complete a daily assessment for adverse eventsMeasure: Incidence of Treatment-Emergent Adverse Events Time: 28 days
Description: Admission to HospitalMeasure: Rate of Hospitalization Time: 28 days
Description: Oxygen saturationMeasure: Change in Oxygen Saturation Time: 8 days
Description: Body temperatureMeasure: Change in Body Temperature Time: 8 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports